Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Open Access
- 15 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 11 (6), 1524-1541
- https://doi.org/10.1158/2159-8290.cd-20-0812
Abstract
Loss of the NFκB pathway inhibitor TRAF3 increased MHC-I expression, improving T cell–mediated cancer cell killing and tumor responsiveness to immune checkpoint blockade, an effect that could be mimicked with the drug birinapant.Keywords
Other Versions
Funding Information
- NIH (R01CA234018)
- NIH (R01AI137337)
- NIH (P50CA101942-12, P50CA206963)
This publication has 92 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell IdentitiesMolecular Cell, 2010
- TRAF3 Controls Activation of the Canonical and Alternative NFκB by the Lymphotoxin Beta ReceptorOnline Journal of Public Health Informatics, 2010
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Highly parallel identification of essential genes in cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2008
- Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signalingNature Immunology, 2008
- Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIKNature Immunology, 2008
- Shared Principles in NF-κB SignalingCell, 2008
- The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cellsThe Journal of Experimental Medicine, 2006